128
Participants
Start Date
June 11, 2024
Primary Completion Date
June 15, 2026
Study Completion Date
June 15, 2026
PNH-relevant therapies
This is an observational study. There is no treatment allocation. The decision to initiate PNH-relevant therapies (such as eculizumab, ravulizumab, pegcetacoplan, iptacopan, and others) will be based solely on clinical judgement.
RECRUITING
Novartis Investigative Site, East Hanover
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY